Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
67
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,676.76 | 665.80 | -1.27% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,322.46 | 862.26 | -3.29% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,553.68 | 166.71 | -2.16% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |